1 day Ago By Defense World Staff
Thrivent Financial for Lutherans lowered its position in shares of Omnicell, Inc. (NASDAQ:OMCL – Free Report) by 0.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
The fund owned 35,801 shares of the company’s stock after selling 317 shares during the period. Thrivent Financial for Lutherans owned approximately 0.08% of Omnicell worth $1,594,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently made changes to their positions in the company. Sumitomo Mitsui Trust Group Inc. raised its position in Omnicell by 93.
3% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock valued at $64,573,000 after purchasing an additional 699,925 shares during the period.
Victory Capital Management Inc. raised its holdings in Omnicell by 32.9% in the 4th quarter.
Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock valued at $67,951,000 after buying an additional 377,883 shares during the period. ArrowMark Colorado Holdings LLC raised its holdings in Omnicell by 27.
1% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock valued at $49,742,000 after buying an additional 243,353 shares during the period. Connor Clark & Lunn Investment Management Ltd.
lifted its position in Omnicell by 46.1% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd.
now owns 429,687 shares of the company’s stock valued at $19,130,000 after buying an additional 135,650 shares during the last quarter. Finally, Pier Capital LLC purchased a new position in Omnicell during the third quarter worth about $5,859,000. Hedge funds and other institutional investors own 97.
70% of the company’s stock. Omnicell Stock Down 1.0 %Omnicell stock opened at $35.
01 on Monday. The firm has a market capitalization of $1.64 billion, a P/E ratio of 129.
67, a P/E/G ratio of 7.53 and a beta of 0.85.
The stock’s fifty day simple moving average is $39.01 and its 200-day simple moving average is $42.57.
Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $55.
75. The company has a current ratio of 1.37, a quick ratio of 1.
22 and a debt-to-equity ratio of 0.13. Omnicell (NASDAQ:OMCL – Get Free Report) last posted its quarterly earnings results on Thursday, February 6th.
The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.
12). Omnicell had a net margin of 1.13% and a return on equity of 3.
82%. As a group, equities analysts expect that Omnicell, Inc. will post 1.
09 earnings per share for the current fiscal year. Wall Street Analyst Weigh InSeveral brokerages have recently commented on OMCL. Bank of America decreased their price objective on shares of Omnicell from $54.
00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. StockNews.
com cut Omnicell from a “buy” rating to a “hold” rating in a research note on Monday, March 24th. Benchmark restated a “buy” rating and set a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th.
Wells Fargo & Company cut their price objective on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th.
Finally, JPMorgan Chase & Co. decreased their target price on Omnicell from $44.00 to $36.
00 and set a “neutral” rating on the stock in a research note on Thursday, March 20th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.
com, Omnicell presently has a consensus rating of “Hold” and a consensus price target of $51.00.Read Our Latest Analysis on OMCLAbout Omnicell (Free Report)Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally.
The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.Further ReadingFive stocks we like better than OmnicellHow to Use the MarketBeat Stock Screener Venezuelan Tariffs Could Power These 3 Diesel-Driven WinnersWhy Invest in High-Yield Dividend Stocks?MarketBeat Week in Review – 03/24 – 03/28How to Invest in the Best Canadian Stocks Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low.
